OGN Latest Press Releases

-- June 10, 2026 --

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19 Business Wire 7:30 AM

-- June 9, 2026 --

Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders Globe Newswire 8:04 PM

-- May 15, 2026 --

Organon to Present New Research on Access and Value at ISPOR 2026 Business Wire 7:30 AM

-- May 14, 2026 --

Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders? PRNewswire 5:25 PM

-- May 6, 2026 --

Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders Globe Newswire 9:14 PM

-- May 5, 2026 --

Halper Sadeh LLC is Investigating Whether SLNO, OGN, RMAX, XOMA are Obtaining Fair Deals for their Shareholders Globe Newswire 3:58 PM

Halper Sadeh LLC is Investigating Whether MKC, LEG, OGN, KW are Obtaining Fair Deals for their Shareholders Globe Newswire 2:53 PM

Halper Sadeh LLC is Investigating Whether AVNS, OGN, ESQ, VRE are Obtaining Fair Deals for their Shareholders Globe Newswire 12:58 PM

-- May 4, 2026 --

Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? PRNewswire 2:55 PM

-- April 30, 2026 --

Organon Reports Results for the First Quarter Ended March 31, 2026 Business Wire 7:30 AM

-- April 29, 2026 --

European Commission (EC) Approves Henlius and Organon's POHERDY (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe PRNewswire 10:00 AM

Organon Cancels First Quarter Earnings Call Business Wire 7:30 AM

European Commission (EC) Approves Henlius and Organon's POHERDY (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe Business Wire 5:30 AM

-- April 28, 2026 --

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN Business Wire 12:36 PM

-- April 27, 2026 --

Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders Globe Newswire 9:23 PM

Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders? PRNewswire 11:24 AM

Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical Globe Newswire 11:02 AM

OGN Stock Alert: Halper Sadeh LLC is Investigating Whether Organon & Co. is Obtaining a Fair Price for its Shareholders Business Wire 8:20 AM

Shareholder Alert: Ademi LLP investigates whether Organon & Co. is obtaining a Fair Price for Public Shareholders PRNewswire 2:23 AM

-- April 26, 2026 --

Sun Pharma signs Definitive Agreement to Acquire Organon Business Wire 7:51 PM

-- April 16, 2026 --

Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026 Business Wire 7:30 AM

-- April 15, 2026 --

Organon's VTAMA (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis Business Wire 7:30 AM

-- March 27, 2026 --

Organon Debuts New Analysis of VTAMA (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age Business Wire 8:00 AM

-- February 27, 2026 --

New Analysis of Organon's VTAMA (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis Business Wire 8:00 AM

-- February 23, 2026 --

Organon Enters into Agreement to License MIUDELLA, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device Business Wire 7:30 AM

-- February 16, 2026 --

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight PRNewswire 5:31 PM

-- February 12, 2026 --

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025 Business Wire 7:30 AM

-- January 29, 2026 --

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026 Business Wire 7:30 AM

-- January 28, 2026 --

Organon Completes Divestiture of JADA System to Laborie Business Wire 12:45 PM

-- January 16, 2026 --

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque Business Wire 9:12 PM